NASDAQ, NKTR - Nektar Therapeutics

We are a biopharmaceutical company that develops and enables differentiated  therapeutics with our leading PEGylation and pulmonary drug development  technology platforms. Our mission is to create differentiated, innovative  products by applying our platform technologies to established or novel  medicines. By doing so, we aim to raise the standards of current patient care by  improving one or more performance parameters, including efficacy, safety or ease  of use. Ten products using these technology platforms have received regulatory  approval in the U.S. or Europe. Our two technology platforms are the basis of  nearly all of our partnered and proprietary product and product candidates.  We create or enable potential breakthrough products in two ways. First, we  develop products in collaboration with pharmaceutical and biotechnology  companies that seek to improve and differentiate their products.  ...

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	N/A
PEG Ratio:	3.31
EPS:	N/A
DivYield:	N/A
PtB:	22.3668
PtS:	27.79
EBITDA:	N/A
Shares:	12.41M
Market Cap:	286.1M
52wk range:	0.43 - 37.38

216.73.216.229
United States